Frontlight ResearchEarly access
Taking people in CzechiaPhase 4
Monitoring ocrelizumab levels in the blood for people with multiple sclerosis
Checks ocrelizumab blood levels against health measures in adults with multiple sclerosis.
Key facts
- Who runs it
- Fakultni Nemocnice Ostrava
- Where
- Ostrava, CzechiaSee the site
- Trial code
- Registry title
- The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 100 people, planned
- Started
- 16 Jun 2025
- Planned end
- 31 Aug 2026
- Type of study
- Interventional
- Record updated
- 5 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with relapsing-remitting or primary progressive multiple sclerosis who already take ocrelizumab or are starting it.
- Age
- Older than 18 years
- Sex
- Men and women
- Disease stage
- Relapsing-remitting and/or primary progressive multiple sclerosis
- Earlier treatment
- Ocrelizumab treatment already established or newly started
Main reasons for not taking part
- Allergy to ocrelizumab or any of its ingredients
- Current active infection
- Severely weakened immune system
- Known active cancer
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients diagnosed with RR and/or PP RS with already established or newly started OCR treatment
- Men and women older than 18 years
- Signing the Informed Consent to participate in the study
- Female patients of childbearing age who can become pregnant must have a negative result of serum human chorionic gonadotropin (hCG) at the initial visit and use a highly reliable method of contraception with a home control urine pregnancy test every month for the entire duration of the study
Who cannot take part
- Hypersensitivity to the medicinal substance or to any excipient
- Current active infection
- Known active malignant disease
- Patients in a severe immunocompromised state
- Pregnancy or breastfeeding
Where in Czechia
- Fakultni nemocnice OstravaOstrava, CzechiaTaking people
About the trial
What the trial wants to find out
To determine whether and how serum OCR concentrations correlate with selected paraclinical and clinical indicators in patients with relapsing-remitting and/or primary progressive MS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis
- Plain-language title
- Monitoring ocrelizumab levels in the blood for people with multiple sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 5 September 2025